Science News
from research organizations

Biomarkers in cerebrospinal fluid can identify patients with Alzheimer's disease

Date:
October 22, 2012
Source:
University of Gothenburg
Summary:
Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer’s disease from those with other types of dementia. The method may eventually permit earlier detection of Alzheimer’s disease.
Share:
       
FULL STORY

Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer's disease from those with other types of dementia. The method, which is being studied by researchers at Sahlgrenska Academy, may eventually permit earlier detection of Alzheimer's disease.

Due to the similarity of the symptoms, differentiating patients with Alzheimer's from those with other types of dementia -- or patients with Parkinson'sdisease from those with other motor disorders -- is often difficult.

Making a proper diagnosis is essential if proper treatment and medication are to commence at an early stage. A research team at Sahlgrenska Academy, University of Gothenburg, is developing a new method to differentiate patients with Alzheimer's disease or Parkinson disease by analyzing a cerebrospinal fluid sample.

The study, led by Professor Kaj Blennow and conducted among 450 patients at Skåne University Hospital and Sahlgrenska University Hospital, involved testing five proteins that serve as biomarkers for the two diseases.

"Previous studies have shown that Alzheimer's disease is associated with biochemical changes in specific proteins of the brain," says Annika Öhrfelt, a researcher at Sahlgrenska Academy. "This study has found that the inclusion of a new protein can differentiate patients with Alzheimer's disease from those with Lewy body dementia, Parkinson disease dementia and other types of dementia."

Similarly, the biomarkers can differentiate patients with Parkinson disease from those with atypical Parkinsonian disorders.

"Additional studies are needed before the biomarkers can be used in clinical practice during the early stages of disease," says Öhrfelt, "but these results represent an important step along the way."



Story Source:

The above post is reprinted from materials provided by University of Gothenburg. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sara Hall, Annika Öhrfelt, Radu Constantinescu, Ulf Andreasson, Yulia Surova, Fredrik Bostrom, Christer Nilsson, Håkan Widner, Hilde Decraemer, Katarina Nägga, Lennart Minthon, Elisabet Londos, Eugeen Vanmechelen, Björn Holmberg,Henrik Zetterberg, Kaj Blennow, Oskar Hansson. Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients with Dementia and/or Parkinsonian Disorders. Arch Neurol., 2012 DOI: 10.1001/archneurol.2012.1654

Cite This Page:

University of Gothenburg. "Biomarkers in cerebrospinal fluid can identify patients with Alzheimer's disease." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022080142.htm>.
University of Gothenburg. (2012, October 22). Biomarkers in cerebrospinal fluid can identify patients with Alzheimer's disease. ScienceDaily. Retrieved July 31, 2015 from www.sciencedaily.com/releases/2012/10/121022080142.htm
University of Gothenburg. "Biomarkers in cerebrospinal fluid can identify patients with Alzheimer's disease." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022080142.htm (accessed July 31, 2015).

Share This Page: